Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: A clinical and cost evaluation

Supportive Care in Cancer

Volumn 20, Issue 8, 2012, Pages 1805-1810

  Hayashi, Toshinobu ^b   Ikesue, Hiroaki ^a   Esaki, Taito ^b   Fukazawa, Mami ^b   Abe, Motoaki ^b   Ohno, Shinji ^b   Tomizawa, Tatsuru ^b   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Antiemetics; Cost minimization analysis; Dexamethasone; Docetaxel; Low emetic risk chemotherapy

Indexed keywords

AZASETRON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANISETRON; ONDANSETRON;

ADULT; ANTIEMETIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST CONTROL; COST MINIMIZATION ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DYSPEPSIA; HEALTH CARE PLANNING; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; CONSTIPATION; COST SAVINGS; DEXAMETHASONE; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; ONDANSETRON; PRACTICE GUIDELINES AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS; TAXOIDS; VOMITING;

EID: 84863982206     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1278-6     Document Type: Article

References (25)

1. Berard CM, Mahoney CD (1995) Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Am J Health Syst Pharm 52:1879-1885
2. Dranitsaris G, Warr D, Puodziunas A (1995) A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 3:183-189
3. Nolte MJ, Berkery R, Pizzo B et al (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16:771-778
4. Brown RS, Brown TK, Hoare D et al (1998) An audit of antiemetic use with CMF chemotherapy. Clin Oncol 10:313-317
5. Engstrom C, Hernandez I, Haywood J et al (1999) The efficacy and cost effectiveness of new antiemetic guidelines. Oncol Nurs Forum 26:1453-1458
6. Walker PC, Biglin KE, Constance TD et al (2001) Promoting the use of oral ondansetron in children receiving cancer chemotherapy. Am J Health Syst Pharm 58:598-602
7. Dranitsaris G, Leung P,Warr D (2001) Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 9:611-618
8. McCune JS, Oertel MD, Pfeifer D et al (2001) Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study. Ann Pharmacother 35:14-20
9. Steiner MA, Yorgason RZ, Vermeulen LC et al (2003) Patient outcomes after therapeutic interchange of dolasetron for granisetron. Am J Health Syst Pharm 60:1023-1028
10. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947
11. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
12. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
13. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. Antiemesis. V.2.2010. http://www.nccn.org/professionals/ physician-gls/PDF/antiemesis.pdf.Accessed June 2010
14. Herrstedt J, Aapro MS, Smyth JF et al (1998) Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6:204-214
15. Braithwaite SS, Barr WG, Rahman A et al (1998) Managing diabetes during glucocorticoid therapy. How to avoid metabolic emergencies. Postgrad Med 104:163-176
16. Italian Group for Antiemetic Research (2004) Cancer patients submitted to innovative chemotherapeutic agents of intermediate emetic potential: antiemetic prescriptions and incidence of emesis. Tumori 90:103-106
17. Molassiotis A, Saunders MP, Valle J et al (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201-208
18. Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emeticity: an update. Support Care Cancer 13:80-84
19. Kataoka A, Ohno S, Sagara Y et al (2005) Team approach to providing the multidisciplinary medical treatment derived by the patients and their family. Breast Cancer 12:21-25
20. The Statistics Bureau, Ministry of Internal Affairs and Communications Basic Survey onWage Structure 2008. http://www.e-stat.go.jp/SG1/estat/List.do? bid=000001022183&cycode=0. Accessed 17June 2010 (in Japanese)
21. Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for nodepositive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671
22. National Comprehensive Cancer Network (NCCN) (2010) NCCN clinical practice guidelines in oncology. Breast cancer. V.2.2010.http://www.nccn.org/ professionals/physician-gls/PDF/breast.pdf. Accessed 17 June 2010
23. Vardy J, Chiew KS, Galica J et al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011-1015
24. Italian Group for Antiemetic Research (2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamid. J Clin Oncol 22:725-729
25. Suminaga M, Furue H, Taguchi T et al (1992) Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs-dose-finding study in patients receiving cisplatin. Gan To Kagaku Ryoho 19:1333-1345 (in Japanese)